Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP
Associate Professor
Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Elyse Tung, PharmD, BCACP
Clinical Assistant Professor
University of Washington School of Pharmacy
Director of Clinical Services
Kelley-Ross Pharmacy
Seattle, Washington

Target Audience

The educational design of this activity addresses the needs of clinical pharmacists who contribute to or will contribute to human immunodeficiency virus (HIV) prevention and/or management services.

Statement of Need/Program Overview

With more than 1 million people living with HIV infection in the United States, long-term management across the continuum of care is critical.1 Best-practice recommendations for patients infected with HIV are rapidly evolving, including strategies related to testing, linkage to care, and antiretroviral therapy (ART).2,3 Importantly, survival rates among HIV-infected adults who are retained in care with currently recommended treatment regimens now approach those observed for uninfected adults.4 Often, however, suboptimal access to medical services hinders the optimal management of these patients. Pharmacists are well positioned to help close this gap owing to their accessibility, routine interactions with patients living with HIV, and opportunities to participate collaboratively in HIV testing, patient counseling, and ongoing monitoring of individuals prescribed ART.3,5 In this Point-of-Care 101 webinar, expert faculty will discuss the roles of clinical pharmacists in encouraging the prescription of recommended antiretroviral regimens, promoting therapeutic adherence, and monitoring patients with HIV infection longitudinally. The goal is to improve the ability of practicing pharmacists to manage patients with HIV infection, minimize potential drug interactions with ART, and tailor strategies for special populations, such as older cohorts or those with certain comorbidities.


  1. CDC. Singh S, et al. Presented at Conference on Retroviruses and Opportunistic Infections; February 14, 2017; Seattle, WA. Abstract 30.
  2. DHHS. National HIV/AIDS Strategy: Updated to 2020. https://hab.hrsa.gov/about-ryan-white-hivaids-program/national-hivaids-strategy-updated-2020. Accessed October 5, 2017.
  3. Schafer JJ, et al. ASHP guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73(7):468-494.
  4. Günthard HF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA Panel. JAMA. 2016;316(2):191-210.
  5. Kauffman Y, et al. Identifying medication-related needs of HIV patients: foundation for community pharmacist-based services. Inov Pharm.2014;5(1): Article 139.

Educational Objectives

Upon completion of this activity, the participant should be better able to:

  • Actively collaborate with other health care providers to optimize treatment across the HIV-care continuum
  • Provide consultation to HIV treaters regarding ART-regimen selection, treatment switching and simplification strategies, potential drug-drug interactions, and other pharmacologic considerations
  • Counsel clients/patients regarding ART efficacy, safety, dosing, and monitoring
  • Support clients’/patients’ ART adherence, monitoring compliance, risk-behavior reduction, receipt of recommended immunizations, and general health maintenance

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0530-9999-17-349-H02-P

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation.  Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

System Requirements

Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*

MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this activity: 

Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Grants/Research Support: Merck & Co, Inc.

Elyse Tung, PharmD, BCACP Advisory Board: Gilead Sciences, Inc.; Speakers Bureau: Gilead Sciences, Inc. 

The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this activity:

Lindsay Borvansky  Nothing to disclose
Ashley Marostica, RN, MSN  Nothing to disclose
Andrea Funk Nothing to disclose
Jim Kappler, PhD  Nothing to disclose
Jeanette Ruby, MD  Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommend

Begin Activity